About us

广州市恒诺康医药科技有限公司

Guangzhou Henovcom Bioscience Co., Ltd. was founded in 2013 by biopharmaceutical veterans with extensive experience in the US biopharmaceutical industry R&D and regulatory agencies. The founders have played key roles in the discovery and development of several blockbuster drugs currently on the market.

Henovcom has assembled a highly skilled R&D team and has developed advanced platforms in medicinal chemistry, API process, analytical chemistry, formulation, ADME and clinical development. The company's pipeline is focused on addressing global unmet medical needs in therapeutic areas such as antiviral, anti-fibrotic, inflammation, and central nervous system. Multiple new moleucular entities (NMEs) are currently undergoing clinical trials in both USA and China. Henovcom holds over 70 patents worldwide, with the majority of them already granted.

Drawing on our extensive expertise in nucleoside modifications and nucleic acid chemistry, Henovcom has created an innovative and  highly efficient mRNA capping technology for “one-pot” in vitro transcription of mRNA.  Additionally, the company has developed a proprietary capping agent LZCap^®, along with various modified nucleotides for mRNA synthesis at both research and commercial scale. To cater to the needs of customers globally, Henovcom has established a cutting-edge GMP facility.